FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308977892> ?p ?o ?g. }

• W4308977892 endingPage "vii230" @default.
• W4308977892 startingPage "vii229" @default.
• W4308977892 abstract "Abstract DNA methylation profiling has emerged as a transformative prognostic tool in meningiomas, identifying distinct epigenetic subgroups that share unique clinical and biological features. Hypothesizing that methylation patterns may also reflect underlying pathogenic mechanisms, we investigated if this modality could be informative for the selection of efficacious chemotherapies in meningiomas, focusing on FDA-approved compounds that are well-tolerated in patients. Using a methylation dataset of 210 tumors, we identified 981 genes in which adjacent CpG sites were predictive of progression-free survival. Pathway enrichment of these genes nominated Docetaxel as a candidate therapeutic; a well-established taxane that is routinely used for breast, prostate, and lung cancers. Using 15 primary patient-derived cultures and 2 cell lines, we found that Docetaxel could inhibit meningioma growth at concentrations that were favorable relative to other cancers. This drug triggered apoptosis in meningiomas of all tumor grades and methylation classes, with IC50 values ranging from 0.8nm to 4.4nm in vitro. Combining Docetaxel with radiation therapy resulted in synergistic cytotoxic effects on meningioma cultures, associated with elevated markers of cell death and dsDNA breaks. We confirmed our results via orthotopic meningioma mouse models of the cell lines CH157 and IOMM-Lee, which exhibited dose-dependent improvements in mortality and tumor volume in response to Docetaxel and radiation. Our results leverage DNA methylation patterns to repurpose FDA-approved medications in the treatment of meningiomas, and suggest a clinical trial of Docetaxel with radiotherapy may be efficacious in higher-grade lesions." @default.
• W4308977892 created "2022-11-20" @default.
• W4308977892 creator A5002164393 @default.
• W4308977892 creator A5007181834 @default.
• W4308977892 creator A5007209727 @default.
• W4308977892 creator A5009246073 @default.
• W4308977892 creator A5009670051 @default.
• W4308977892 creator A5009680978 @default.
• W4308977892 creator A5019009732 @default.
• W4308977892 creator A5019552633 @default.
• W4308977892 creator A5020194160 @default.
• W4308977892 creator A5023585542 @default.
• W4308977892 creator A5024048256 @default.
• W4308977892 creator A5032455600 @default.
• W4308977892 creator A5041279285 @default.
• W4308977892 creator A5041982816 @default.
• W4308977892 creator A5043151851 @default.
• W4308977892 creator A5043828700 @default.
• W4308977892 creator A5045290531 @default.
• W4308977892 creator A5050859137 @default.
• W4308977892 creator A5051556128 @default.
• W4308977892 creator A5060733211 @default.
• W4308977892 creator A5063471368 @default.
• W4308977892 creator A5068334608 @default.
• W4308977892 creator A5079081497 @default.
• W4308977892 date "2022-11-01" @default.
• W4308977892 modified "2023-10-14" @default.
• W4308977892 title "EXTH-88. DOCETAXEL TARGETS AGGRESSIVE METHYLATION PROFILES AND SERVES AS A RADIOSENSITIZER IN HIGH-RISK MENINGIOMAS" @default.
• W4308977892 doi "https://doi.org/10.1093/neuonc/noac209.886" @default.
• W4308977892 hasPublicationYear "2022" @default.
• W4308977892 type Work @default.
• W4308977892 citedByCount "1" @default.
• W4308977892 countsByYear W43089778922023 @default.
• W4308977892 crossrefType "journal-article" @default.
• W4308977892 hasAuthorship W4308977892A5002164393 @default.
• W4308977892 hasAuthorship W4308977892A5007181834 @default.
• W4308977892 hasAuthorship W4308977892A5007209727 @default.
• W4308977892 hasAuthorship W4308977892A5009246073 @default.
• W4308977892 hasAuthorship W4308977892A5009670051 @default.
• W4308977892 hasAuthorship W4308977892A5009680978 @default.
• W4308977892 hasAuthorship W4308977892A5019009732 @default.
• W4308977892 hasAuthorship W4308977892A5019552633 @default.
• W4308977892 hasAuthorship W4308977892A5020194160 @default.
• W4308977892 hasAuthorship W4308977892A5023585542 @default.
• W4308977892 hasAuthorship W4308977892A5024048256 @default.
• W4308977892 hasAuthorship W4308977892A5032455600 @default.
• W4308977892 hasAuthorship W4308977892A5041279285 @default.
• W4308977892 hasAuthorship W4308977892A5041982816 @default.
• W4308977892 hasAuthorship W4308977892A5043151851 @default.
• W4308977892 hasAuthorship W4308977892A5043828700 @default.
• W4308977892 hasAuthorship W4308977892A5045290531 @default.
• W4308977892 hasAuthorship W4308977892A5050859137 @default.
• W4308977892 hasAuthorship W4308977892A5051556128 @default.
• W4308977892 hasAuthorship W4308977892A5060733211 @default.
• W4308977892 hasAuthorship W4308977892A5063471368 @default.
• W4308977892 hasAuthorship W4308977892A5068334608 @default.
• W4308977892 hasAuthorship W4308977892A5079081497 @default.
• W4308977892 hasBestOaLocation W43089778921 @default.
• W4308977892 hasConcept C104317684 @default.
• W4308977892 hasConcept C121608353 @default.
• W4308977892 hasConcept C126322002 @default.
• W4308977892 hasConcept C142724271 @default.
• W4308977892 hasConcept C143998085 @default.
• W4308977892 hasConcept C150194340 @default.
• W4308977892 hasConcept C190727270 @default.
• W4308977892 hasConcept C2779160599 @default.
• W4308977892 hasConcept C2781190966 @default.
• W4308977892 hasConcept C33288867 @default.
• W4308977892 hasConcept C502942594 @default.
• W4308977892 hasConcept C54355233 @default.
• W4308977892 hasConcept C71924100 @default.
• W4308977892 hasConcept C86803240 @default.
• W4308977892 hasConceptScore W4308977892C104317684 @default.
• W4308977892 hasConceptScore W4308977892C121608353 @default.
• W4308977892 hasConceptScore W4308977892C126322002 @default.
• W4308977892 hasConceptScore W4308977892C142724271 @default.
• W4308977892 hasConceptScore W4308977892C143998085 @default.
• W4308977892 hasConceptScore W4308977892C150194340 @default.
• W4308977892 hasConceptScore W4308977892C190727270 @default.
• W4308977892 hasConceptScore W4308977892C2779160599 @default.
• W4308977892 hasConceptScore W4308977892C2781190966 @default.
• W4308977892 hasConceptScore W4308977892C33288867 @default.
• W4308977892 hasConceptScore W4308977892C502942594 @default.
• W4308977892 hasConceptScore W4308977892C54355233 @default.
• W4308977892 hasConceptScore W4308977892C71924100 @default.
• W4308977892 hasConceptScore W4308977892C86803240 @default.
• W4308977892 hasIssue "Supplement_7" @default.
• W4308977892 hasLocation W43089778921 @default.
• W4308977892 hasOpenAccess W4308977892 @default.
• W4308977892 hasPrimaryLocation W43089778921 @default.
• W4308977892 hasRelatedWork W1986736445 @default.
• W4308977892 hasRelatedWork W2024405956 @default.
• W4308977892 hasRelatedWork W2046964473 @default.
• W4308977892 hasRelatedWork W2052355316 @default.
• W4308977892 hasRelatedWork W2126563386 @default.
• W4308977892 hasRelatedWork W2128056428 @default.
• W4308977892 hasRelatedWork W2139872319 @default.
• W4308977892 hasRelatedWork W2435756822 @default.

• next